Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

BIOSANTE PHARMACEUTICALS INC

Form 4 July 31, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

5. Relationship of Reporting Person(s) to

(Check all applicable)

Issuer

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

Section 16. Form 4 or Form 5 obligations may continue.

Check this box

if no longer

subject to

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

BIOSANTE PHARMACEUTICALS

Symbol

INC [BPAX]

1(b).

(Print or Type Responses)

MANGANO ROSS J

1. Name and Address of Reporting Person *

See Instruction

(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)				X Director Officer (give	title Othe	Owner er (specify	
P.O. BOX 1655			07/29/2008					below)	below)	
			mendment, Date Original Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
SOUTH BEND, IN 46634								Form filed by More than One Reporting Person		
(City)	(State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year 07/29/2008	e) Execution any	med n Date, if Day/Year)	3. Transactic Code (Instr. 8)	4. Securitie or(A) or Disp (Instr. 3, 4) Amount 146,512	osed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 1,884,661	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4) By JO & Co.
Common Stock								85,756	D	
Common Stock								30,000	I	See footnote (1)
Common Stock								48,333	I	By Trust
Common Stock								33,333	I	By Trust

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

Common Stock	33,333	I	By Trust
Common Stock	100,000	I	See footnote

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of ionDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		tive Expiration Date ties (Month/Day/Year) red (A) or sed of (D)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount of Number of Shares
Warrant (right to buy)	\$ 2.15	07/29/2008		X		146,512	08/04/2003	08/03/2008	Common Stock	146,512

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
MANGANO ROSS J P.O. BOX 1655 SOUTH BEND, IN 46634	X						
0!							

Signatures

/s/ Phillip B. Donenberg, attorney-in-fact 07/30/2008

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares are held by Oliver & Co., of which Mr. Mangano is a trustee.
- (2) Shares are held indirectly by Mr. Mangano in various trusts of which Mr. Mangano is the trustee.

Reporting Owners 2

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

(3) Shares are indirectly held by Mr. Mangano as an investment advisor on behalf of an individual.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.